We explain the recent statement from the UK clinical community.

SIOPEN, the UK National Cancer Research Institute Neuroblastoma Group and the CCLG Neuroblastoma Special Interest Group are committed to further improving the outcome for children with neuroblastoma.

This new clinical trial will be available to children in 40 hospitals across 11 European countries and has been jointly funded by Solving Kids’ Cancer UK and the French charity, Imagine for Margo.

Solving Kids' Cancer UK thanks GamesAid – the UK video games industry based charity – for their important and generous support in 2019.

Solving Kids’ Cancer is pleased to announce that it has awarded a grant of £250,000 to Professor John Anderson of UCL, to study preclinical refinements of treatment of neuroblastoma with CAR-T cells.

A team at Newcastle University are carrying out a neuroblastoma study that is being sponsored by Newcastle upon Tyne Hospitals NHS Trust and funded by Action Medical Research.

We are pleased to see many of our own aims included in the new NHS England Long Term Plan, areas we are working so hard on to improve outcomes for children and families affected by neuroblastoma.

On Friday 14 September and over the weekend that followed, a social media post and related media coverage from the charity Children with Cancer UK called for the supplement melatonin to be made available to children and young people with cancer on the NHS

Families now know their very sick child will be able to have the best treatment that gives the greatest chance of long-term survival here in the UK.